STOCK TITAN

[8-K] FibroBiologics, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

comScore, Inc. (SCOR) – Form 4 insider filing

Director Matthew F. McLaughlin received an equity grant of 10,000 restricted stock units (RSUs) on 07/01/2025 under the company’s 2018 Equity and Incentive Compensation Plan. Each RSU represents one share of common stock.

Vesting schedule: the award vests in full on the earliest of (i) the 2026 annual shareholder meeting, (ii) 30 June 2026, or (iii) a change-of-control event, subject to continued board service. Shares are delivered after separation from service or a change of control.

Compensation changes: the grant’s fair-value target is $120,000, calculated by dividing the target amount by a reference price of $12.00. This represents a significant reduction from the prior director compensation formula, which allocated $170,000 divided by the market price at grant (previously $5.07). The Board reduced overall compensation and applied a higher share price to more closely align directors’ incentives with long-term shareholder value.

Post-transaction ownership: McLaughlin now beneficially owns 10,000 derivative securities (RSUs) held directly; no non-derivative common shares were reported.

The filing is routine and involves no open-market transactions, cash outflow, or immediate dilution; it primarily signals a shift in board compensation structure rather than a material operational event.

comScore, Inc. (SCOR) – Comunicazione Form 4 degli insider

Il direttore Matthew F. McLaughlin ha ricevuto una concessione di 10.000 unità azionarie vincolate (RSU) il 01/07/2025 nell’ambito del Piano di Compensazione Azionaria e Incentivi 2018 della società. Ogni RSU rappresenta un’azione ordinaria.

Calendario di maturazione: il premio matura completamente al primo verificarsi tra (i) l’assemblea annuale degli azionisti del 2026, (ii) il 30 giugno 2026, o (iii) un evento di cambio di controllo, subordinato alla permanenza nel consiglio. Le azioni vengono consegnate dopo la separazione dal servizio o un cambio di controllo.

Modifiche alla compensazione: il valore equo target della concessione è di 120.000 $, calcolato dividendo l’importo target per un prezzo di riferimento di 12,00 $. Ciò rappresenta una significativa riduzione rispetto alla precedente formula di compensazione per i direttori, che prevedeva 170.000 $ divisi per il prezzo di mercato al momento della concessione (precedentemente 5,07 $). Il Consiglio ha ridotto la compensazione complessiva e applicato un prezzo azionario più elevato per allineare maggiormente gli incentivi dei direttori al valore azionario a lungo termine.

Proprietà post-transazione: McLaughlin detiene ora 10.000 titoli derivati (RSU) direttamente; non sono state segnalate azioni ordinarie non derivate.

La comunicazione è di routine e non comporta transazioni sul mercato aperto, esborsi in contanti o diluizione immediata; segnala principalmente un cambiamento nella struttura della compensazione del consiglio piuttosto che un evento operativo significativo.

comScore, Inc. (SCOR) – Presentación Formulario 4 de insider

El director Matthew F. McLaughlin recibió una concesión de capital de 10,000 unidades de acciones restringidas (RSUs) el 01/07/2025 bajo el Plan de Compensación de Capital e Incentivos 2018 de la empresa. Cada RSU representa una acción común.

Calendario de consolidación: la concesión se consolida completamente en la primera de las siguientes fechas: (i) la reunión anual de accionistas de 2026, (ii) el 30 de junio de 2026, o (iii) un evento de cambio de control, sujeto a la continuidad en el consejo. Las acciones se entregan tras la separación del servicio o un cambio de control.

Cambios en la compensación: el valor objetivo justo de la concesión es de $120,000, calculado dividiendo el monto objetivo por un precio de referencia de $12.00. Esto representa una reducción significativa respecto a la fórmula anterior de compensación para directores, que asignaba $170,000 dividido por el precio de mercado al momento de la concesión (anteriormente $5.07). La Junta redujo la compensación total y aplicó un precio por acción más alto para alinear mejor los incentivos de los directores con el valor a largo plazo para los accionistas.

Propiedad post-transacción: McLaughlin ahora posee beneficiosamente 10,000 valores derivados (RSUs) en forma directa; no se reportaron acciones comunes no derivadas.

La presentación es rutinaria y no implica transacciones en el mercado abierto, salida de efectivo o dilución inmediata; principalmente indica un cambio en la estructura de compensación del consejo en lugar de un evento operativo material.

comScore, Inc. (SCOR) – 내부자 신고서 Form 4

이사 Matthew F. McLaughlin은 2025년 7월 1일 회사의 2018년 주식 및 인센티브 보상 계획에 따라 10,000개의 제한 주식 단위(RSU)를 부여받았습니다. 각 RSU는 보통주 1주를 나타냅니다.

권리 확정 일정: 해당 수여는 (i) 2026년 연례 주주총회, (ii) 2026년 6월 30일, 또는 (iii) 지배권 변경 이벤트 중 가장 이른 시점에 전액 확정되며, 계속 이사회에 재직 중일 경우에 한합니다. 주식은 퇴직 또는 지배권 변경 후에 지급됩니다.

보상 변경 사항: 수여의 공정 가치 목표는 120,000달러로, 목표 금액을 기준 가격 12.00달러로 나누어 계산되었습니다. 이는 이전 이사 보상 공식에서 상당히 감소한 금액으로, 이전에는 170,000달러를 수여 시점 시장 가격(이전 5.07달러)으로 나누어 산정했습니다. 이사회는 전체 보상을 줄이고 더 높은 주가를 적용하여 이사들의 인센티브를 장기 주주 가치와 더 밀접하게 연동시켰습니다.

거래 후 소유 현황: McLaughlin은 현재 직접 10,000개의 파생 증권(RSU)을 보유하고 있으며, 비파생 보통주는 보고되지 않았습니다.

이 신고는 일상적인 것으로 공개 시장 거래, 현금 유출 또는 즉각적인 희석 효과가 없으며, 주로 이사회 보상 구조의 변화를 알리는 것으로 중대한 운영 이벤트는 아닙니다.

comScore, Inc. (SCOR) – Déclaration Formulaire 4 des initiés

Le directeur Matthew F. McLaughlin a reçu une attribution de 10 000 unités d’actions restreintes (RSU) le 01/07/2025 dans le cadre du Plan de rémunération en actions et incitatifs 2018 de la société. Chaque RSU représente une action ordinaire.

Calendrier d’acquisition des droits : l’attribution sera entièrement acquise à la première date parmi (i) l’assemblée annuelle des actionnaires 2026, (ii) le 30 juin 2026, ou (iii) un événement de changement de contrôle, sous réserve de la poursuite du service au conseil. Les actions sont délivrées après la séparation du service ou un changement de contrôle.

Modifications de la rémunération : la valeur cible à la juste valeur de l’attribution est de 120 000 $, calculée en divisant le montant cible par un prix de référence de 12,00 $. Cela représente une réduction significative par rapport à la formule de rémunération précédente pour les administrateurs, qui attribuait 170 000 $ divisés par le prix du marché au moment de l’attribution (précédemment 5,07 $). Le Conseil a réduit la rémunération globale et appliqué un prix par action plus élevé afin d’aligner davantage les incitations des administrateurs avec la valeur actionnariale à long terme.

Propriété après la transaction : McLaughlin détient désormais directement 10 000 titres dérivés (RSU) ; aucune action ordinaire non dérivée n’a été déclarée.

La déclaration est de routine et n’implique aucune transaction sur le marché ouvert, sortie de trésorerie ou dilution immédiate ; elle signale principalement un changement dans la structure de rémunération du conseil plutôt qu’un événement opérationnel important.

comScore, Inc. (SCOR) – Form 4 Insider-Meldung

Direktor Matthew F. McLaughlin erhielt am 01.07.2025 eine Zuteilung von 10.000 Restricted Stock Units (RSUs) im Rahmen des Equity- und Incentive-Vergütungsplans 2018 des Unternehmens. Jede RSU entspricht einer Stammaktie.

Vesting-Zeitplan: Die Zuteilung wird vollständig fällig am frühesten Zeitpunkt von (i) der Hauptversammlung 2026, (ii) dem 30. Juni 2026 oder (iii) einem Kontrollwechselereignis, vorausgesetzt, die Vorstandsmitgliedschaft wird fortgesetzt. Die Aktien werden nach Ausscheiden aus dem Dienst oder einem Kontrollwechsel geliefert.

Änderungen der Vergütung: Der beizulegende Zeitwert der Zuteilung beträgt 120.000 $, berechnet durch Division des Zielbetrags durch einen Referenzpreis von 12,00 $. Dies stellt eine erhebliche Reduzierung gegenüber der vorherigen Vergütungsformel für Direktoren dar, die 170.000 $ durch den Marktpreis zum Zeitpunkt der Zuteilung (vorher 5,07 $) teilte. Der Vorstand hat die Gesamtvergütung reduziert und einen höheren Aktienkurs angewandt, um die Anreize der Direktoren besser an den langfristigen Aktionärswert anzupassen.

Eigentumsverhältnisse nach der Transaktion: McLaughlin besitzt nun 10.000 derivative Wertpapiere (RSUs) direkt; nicht-derivative Stammaktien wurden nicht gemeldet.

Die Meldung ist routinemäßig und beinhaltet keine Transaktionen am offenen Markt, keine Geldabflüsse oder sofortige Verwässerung; sie signalisiert hauptsächlich eine Änderung der Vorstandsvergütungsstruktur und kein wesentliches operatives Ereignis.

Positive
  • Director compensation lowered to $120,000 from $170,000, signalling cost discipline and stronger alignment with shareholders.
  • No cash expense; equity-based compensation preserves liquidity while limiting dilution to only 10,000 shares.
Negative
  • Minor dilution from issuance of 10,000 new shares when RSUs settle, although impact is negligible given SCOR’s share count.

Insights

TL;DR – Routine RSU grant, slightly shareholder-friendly due to lower pay target.

The award is standard annual board compensation but the Board cut the target from $170k to $120k and used a higher $12 reference price, reducing share count versus prior practice. At today’s ~$**share price** (not provided here), the grant could be modestly anti-dilutive compared with history. No insider buying or selling occurred, so market impact is minimal. Overall, the move modestly improves pay-for-performance alignment yet is not financially material to SCOR’s capital structure.

comScore, Inc. (SCOR) – Comunicazione Form 4 degli insider

Il direttore Matthew F. McLaughlin ha ricevuto una concessione di 10.000 unità azionarie vincolate (RSU) il 01/07/2025 nell’ambito del Piano di Compensazione Azionaria e Incentivi 2018 della società. Ogni RSU rappresenta un’azione ordinaria.

Calendario di maturazione: il premio matura completamente al primo verificarsi tra (i) l’assemblea annuale degli azionisti del 2026, (ii) il 30 giugno 2026, o (iii) un evento di cambio di controllo, subordinato alla permanenza nel consiglio. Le azioni vengono consegnate dopo la separazione dal servizio o un cambio di controllo.

Modifiche alla compensazione: il valore equo target della concessione è di 120.000 $, calcolato dividendo l’importo target per un prezzo di riferimento di 12,00 $. Ciò rappresenta una significativa riduzione rispetto alla precedente formula di compensazione per i direttori, che prevedeva 170.000 $ divisi per il prezzo di mercato al momento della concessione (precedentemente 5,07 $). Il Consiglio ha ridotto la compensazione complessiva e applicato un prezzo azionario più elevato per allineare maggiormente gli incentivi dei direttori al valore azionario a lungo termine.

Proprietà post-transazione: McLaughlin detiene ora 10.000 titoli derivati (RSU) direttamente; non sono state segnalate azioni ordinarie non derivate.

La comunicazione è di routine e non comporta transazioni sul mercato aperto, esborsi in contanti o diluizione immediata; segnala principalmente un cambiamento nella struttura della compensazione del consiglio piuttosto che un evento operativo significativo.

comScore, Inc. (SCOR) – Presentación Formulario 4 de insider

El director Matthew F. McLaughlin recibió una concesión de capital de 10,000 unidades de acciones restringidas (RSUs) el 01/07/2025 bajo el Plan de Compensación de Capital e Incentivos 2018 de la empresa. Cada RSU representa una acción común.

Calendario de consolidación: la concesión se consolida completamente en la primera de las siguientes fechas: (i) la reunión anual de accionistas de 2026, (ii) el 30 de junio de 2026, o (iii) un evento de cambio de control, sujeto a la continuidad en el consejo. Las acciones se entregan tras la separación del servicio o un cambio de control.

Cambios en la compensación: el valor objetivo justo de la concesión es de $120,000, calculado dividiendo el monto objetivo por un precio de referencia de $12.00. Esto representa una reducción significativa respecto a la fórmula anterior de compensación para directores, que asignaba $170,000 dividido por el precio de mercado al momento de la concesión (anteriormente $5.07). La Junta redujo la compensación total y aplicó un precio por acción más alto para alinear mejor los incentivos de los directores con el valor a largo plazo para los accionistas.

Propiedad post-transacción: McLaughlin ahora posee beneficiosamente 10,000 valores derivados (RSUs) en forma directa; no se reportaron acciones comunes no derivadas.

La presentación es rutinaria y no implica transacciones en el mercado abierto, salida de efectivo o dilución inmediata; principalmente indica un cambio en la estructura de compensación del consejo en lugar de un evento operativo material.

comScore, Inc. (SCOR) – 내부자 신고서 Form 4

이사 Matthew F. McLaughlin은 2025년 7월 1일 회사의 2018년 주식 및 인센티브 보상 계획에 따라 10,000개의 제한 주식 단위(RSU)를 부여받았습니다. 각 RSU는 보통주 1주를 나타냅니다.

권리 확정 일정: 해당 수여는 (i) 2026년 연례 주주총회, (ii) 2026년 6월 30일, 또는 (iii) 지배권 변경 이벤트 중 가장 이른 시점에 전액 확정되며, 계속 이사회에 재직 중일 경우에 한합니다. 주식은 퇴직 또는 지배권 변경 후에 지급됩니다.

보상 변경 사항: 수여의 공정 가치 목표는 120,000달러로, 목표 금액을 기준 가격 12.00달러로 나누어 계산되었습니다. 이는 이전 이사 보상 공식에서 상당히 감소한 금액으로, 이전에는 170,000달러를 수여 시점 시장 가격(이전 5.07달러)으로 나누어 산정했습니다. 이사회는 전체 보상을 줄이고 더 높은 주가를 적용하여 이사들의 인센티브를 장기 주주 가치와 더 밀접하게 연동시켰습니다.

거래 후 소유 현황: McLaughlin은 현재 직접 10,000개의 파생 증권(RSU)을 보유하고 있으며, 비파생 보통주는 보고되지 않았습니다.

이 신고는 일상적인 것으로 공개 시장 거래, 현금 유출 또는 즉각적인 희석 효과가 없으며, 주로 이사회 보상 구조의 변화를 알리는 것으로 중대한 운영 이벤트는 아닙니다.

comScore, Inc. (SCOR) – Déclaration Formulaire 4 des initiés

Le directeur Matthew F. McLaughlin a reçu une attribution de 10 000 unités d’actions restreintes (RSU) le 01/07/2025 dans le cadre du Plan de rémunération en actions et incitatifs 2018 de la société. Chaque RSU représente une action ordinaire.

Calendrier d’acquisition des droits : l’attribution sera entièrement acquise à la première date parmi (i) l’assemblée annuelle des actionnaires 2026, (ii) le 30 juin 2026, ou (iii) un événement de changement de contrôle, sous réserve de la poursuite du service au conseil. Les actions sont délivrées après la séparation du service ou un changement de contrôle.

Modifications de la rémunération : la valeur cible à la juste valeur de l’attribution est de 120 000 $, calculée en divisant le montant cible par un prix de référence de 12,00 $. Cela représente une réduction significative par rapport à la formule de rémunération précédente pour les administrateurs, qui attribuait 170 000 $ divisés par le prix du marché au moment de l’attribution (précédemment 5,07 $). Le Conseil a réduit la rémunération globale et appliqué un prix par action plus élevé afin d’aligner davantage les incitations des administrateurs avec la valeur actionnariale à long terme.

Propriété après la transaction : McLaughlin détient désormais directement 10 000 titres dérivés (RSU) ; aucune action ordinaire non dérivée n’a été déclarée.

La déclaration est de routine et n’implique aucune transaction sur le marché ouvert, sortie de trésorerie ou dilution immédiate ; elle signale principalement un changement dans la structure de rémunération du conseil plutôt qu’un événement opérationnel important.

comScore, Inc. (SCOR) – Form 4 Insider-Meldung

Direktor Matthew F. McLaughlin erhielt am 01.07.2025 eine Zuteilung von 10.000 Restricted Stock Units (RSUs) im Rahmen des Equity- und Incentive-Vergütungsplans 2018 des Unternehmens. Jede RSU entspricht einer Stammaktie.

Vesting-Zeitplan: Die Zuteilung wird vollständig fällig am frühesten Zeitpunkt von (i) der Hauptversammlung 2026, (ii) dem 30. Juni 2026 oder (iii) einem Kontrollwechselereignis, vorausgesetzt, die Vorstandsmitgliedschaft wird fortgesetzt. Die Aktien werden nach Ausscheiden aus dem Dienst oder einem Kontrollwechsel geliefert.

Änderungen der Vergütung: Der beizulegende Zeitwert der Zuteilung beträgt 120.000 $, berechnet durch Division des Zielbetrags durch einen Referenzpreis von 12,00 $. Dies stellt eine erhebliche Reduzierung gegenüber der vorherigen Vergütungsformel für Direktoren dar, die 170.000 $ durch den Marktpreis zum Zeitpunkt der Zuteilung (vorher 5,07 $) teilte. Der Vorstand hat die Gesamtvergütung reduziert und einen höheren Aktienkurs angewandt, um die Anreize der Direktoren besser an den langfristigen Aktionärswert anzupassen.

Eigentumsverhältnisse nach der Transaktion: McLaughlin besitzt nun 10.000 derivative Wertpapiere (RSUs) direkt; nicht-derivative Stammaktien wurden nicht gemeldet.

Die Meldung ist routinemäßig und beinhaltet keine Transaktionen am offenen Markt, keine Geldabflüsse oder sofortige Verwässerung; sie signalisiert hauptsächlich eine Änderung der Vorstandsvergütungsstruktur und kein wesentliches operatives Ereignis.

0001958777false00019587772025-07-012025-07-01

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 01, 2025

 

 

FibroBiologics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-41934

86-3329066

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

455 E. Medical Center Blvd, Suite 300

 

Houston, Texas

 

77598

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 281 671-5150

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.00001 par value

 

FBLG

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On July 1, 2025, FibroBiologics, Inc. (the “Company”) received a notification letter from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the closing bid price of the Company’s shares of common stock was below the minimum closing bid price of $1.00 per share during the last 30 consecutive trading days (the “Notice”), as required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).

The Notice has no immediate impact on the listing of the Company’s common stock, which will continue to be listed and traded on The Nasdaq Capital Market subject to the Company’s continued compliance with the other listing requirements.

In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until December 29, 2025, to regain compliance with this requirement. To regain compliance, the closing bid price of the Company’s common stock must be $1.00 per share or more for a minimum of 10 consecutive business days at any time before December 29, 2025. If the Company does not regain compliance with Rule 5550(a)(2) by December 29, 2025, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, except the bid price requirement, and will need to provide written notice to Nasdaq of its intention to cure the deficiency during the second compliance period. If it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will notify the Company that its securities will be subject to delisting. In the event of such notification, the Company may appeal the Staff’s determination to delist its securities, but there can be no assurance the Staff will grant the Company’s request for continued listing.

The Company will continue to monitor the closing bid price of its common stock and may, as appropriate, consider available options to regain compliance.

This Current Report on Form 8-K is filed to satisfy the obligation under Nasdaq Listing Rule 5810(b) and Item 3.01(a) of Form 8-K that the Company publicly disclose the receipt of the Notice within four (4) business days after the date of the Notice.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

FibroBiologics, Inc.

 

 

 

 

Date:

July 3, 2025

By:

/s/ Pete O'Heeron

 

 

 

Name: Pete O'Heeron
Title: Chief Executive Officer

 


FAQ

What did comScore (SCOR) disclose in the latest Form 4?

Director Matthew F. McLaughlin received 10,000 RSUs valued at $120,000 as part of 2025-2026 board compensation.

When will the 10,000 RSUs granted to Director McLaughlin vest?

They vest on the earliest of the 2026 annual meeting, June 30 2026, or a change in control, subject to continued board service.

How does the new director compensation compare to the prior program?

The target value dropped to $120,000 from $170,000 and uses a $12 reference price, reducing both cost and share count.

Does the Form 4 indicate insider buying or selling of SCOR shares?

No. The filing records an equity award; there were no open-market purchases or sales.

Will the RSU grant cause immediate dilution for shareholders?

No immediate dilution occurs; dilution arises only when the units convert to common shares after vesting and settlement.
Fibrobiologics

NASDAQ:FBLG

FBLG Rankings

FBLG Latest News

FBLG Stock Data

27.94M
30.07M
23.2%
16.98%
5.62%
Biotechnology
Pharmaceutical Preparations
Link
United States
HOUSTON